MASSDEVICE ON CALL — Former FDA commissioner Andrew von Eschenbach turned heads yesterday by calling on the federal watchdog agency to abandon efficacy testing when considering new drug and device applications.
Eschenbach, who led the agency from 2006 to 2009, called for an overhaul of the FDA’s mission statement and urged Congress to leverage user fee negotiations to reassess the agency’s performance.